Fetal bovine serum is collected by drawing blood from the hearts of unborn calves after their pregnant mothers are slaughtered at commercial abattoirs. The process, known as cardiac puncture, happens after the fetus is removed from the carcass of a cow that was typically sent to slaughter without anyone knowing she was pregnant. Globally, more than two million bovine fetuses are used each year to produce roughly 800,000 liters of FBS, making it one of the most widely used and most ethically contested materials in biomedical research.1PubMed Central. Review of the Current Research on Fetal Bovine Serum and the Development of Cultured Meat
Where the Fetuses Come From
FBS is a byproduct of the meat industry, not a product that drives slaughter on its own. The pregnant animals that supply fetuses come from three main sources: culled dairy cows, culled beef cows, and occasionally feedlot heifers. Dairy cows tend to be culled at younger ages than beef cows, and because of how dairy production works, culled dairy cows are frequently still pregnant when sent to slaughter. Beef cows, on the other hand, are often culled precisely because they had trouble getting pregnant again, so a smaller proportion of them arrive at the slaughterhouse carrying a fetus. The beef cow herd is roughly three times the size of the dairy herd, but the higher pregnancy rate among culled dairy cows partly offsets that numerical advantage. Pregnant feedlot heifers are uncommon.2Translational Animal Science. Production, pricing, and incentives in the fetal bovine serum market
In most cases, slaughterhouse workers discover the pregnancy only after the cow has been killed and the carcass is being processed. The fetus is then set aside for serum collection if it is past roughly one month of gestation. This incidental discovery is part of what makes FBS supply so unpredictable: you cannot order more pregnant cows the way you might order more of any other industrial input.
The Collection Procedure Step by Step
Once the fetus is removed from its mother’s carcass, it is transferred to a sterile area within the slaughterhouse or an adjacent government-approved collection facility. The exterior of the fetus is disinfected to prevent bacterial contamination of the blood. A large-gauge needle is then inserted directly into the fetal heart, and blood is drawn by cardiac puncture. This method is used because the heart contains the largest accessible volume of blood in a fetus, and withdrawing it in a single puncture minimizes contamination compared to drawing from smaller vessels.1PubMed Central. Review of the Current Research on Fetal Bovine Serum and the Development of Cultured Meat
The volume of blood recovered depends on the gestational age and size of the fetus. Younger, smaller fetuses yield very little usable blood, while fetuses closer to term can yield substantially more. Even so, an individual fetus produces only a small quantity of serum, which is one reason millions of fetuses are needed annually to meet global demand.
Turning Blood Into Serum
What comes out of the fetus is whole blood, not serum. Converting it into the clear, yellowish liquid that researchers actually use requires several processing steps. The collected blood is placed in sterile containers and refrigerated. Cold temperatures promote coagulation, allowing the blood to clot naturally. As the clot forms, it traps red blood cells, white blood cells, platelets, and clotting factors into a solid mass. The liquid that remains after clotting is the serum.1PubMed Central. Review of the Current Research on Fetal Bovine Serum and the Development of Cultured Meat
After clotting is complete, the mixture is centrifuged under refrigeration. The centrifuge spins the clotted blood at high speed, separating the dense cellular debris from the lighter serum. The resulting clear yellow fluid is then filtered through progressively finer membranes to remove remaining particles and microorganisms. At the end of this chain, the serum is bottled, labeled by lot, and frozen for storage and shipment.
Why FBS Is So Valuable for Cell Culture
FBS became the standard supplement for growing cells in laboratories because of its unusual biological profile. Fetal blood has very low levels of immunoglobulins, the antibodies that an adult animal’s immune system produces throughout its life. Because the fetus has not yet mounted significant immune responses, its serum does not trigger the immune reactions in cultured cells that adult serum would. At the same time, fetal serum is rich in growth factors, hormones, amino acids, vitamins, and proteins that cells need to divide and thrive.1PubMed Central. Review of the Current Research on Fetal Bovine Serum and the Development of Cultured Meat
This combination of low antibody interference and high growth stimulation is difficult to replicate synthetically. FBS works across a wide range of cell types from many different species, which is why it shows up in everything from basic cancer research to vaccine manufacturing to the emerging field of cultivated meat. Its versatility is also its problem: researchers and manufacturers in dozens of fields all compete for the same limited supply.
Pathogen Safety and Sterilization
Raw serum collected from an animal fetus is not automatically safe for use in sensitive laboratory applications. It can harbor viruses, mycoplasmas, and other contaminants that would ruin an experiment or, worse, contaminate a therapeutic cell product intended for human use. To address this, producers employ several decontamination methods.
Gamma irradiation is one of the most widely used techniques for inactivating viruses and mycoplasma-like organisms (called mollicutes) in animal sera. Standard doses in the range of 25 to 40 kilograys effectively eliminate mollicutes, though the success with viruses depends partly on the size of the virus: smaller viruses tend to be harder to inactivate because their genetic material presents a smaller target for the radiation.3PubMed Central. Gamma irradiation of animal sera for inactivation of viruses and mollicutes–a review Other methods include heat inactivation, where serum is held at 56°C for 30 minutes to destroy complement proteins and some pathogens, and triple-filtration through 0.1-micrometer membranes. The choice of method depends on what the serum will be used for and how stringent the regulatory requirements are.
The Animal Welfare Debate
The ethical controversy around FBS collection centers on whether the fetal calf suffers during the process. An adult cow is killed by standard slaughter methods, and the fetus is removed from the carcass afterward. But the timing matters: if the fetus is still alive when blood is drawn by cardiac puncture, the question is whether it experiences pain. This is not a settled issue. There is active ethical debate about whether fetal calves are conscious or can feel distress at the developmental stages when blood is typically collected.4PubMed. Addressing Animal Welfare Issues in Fetal Blood Collection for Fetal Bovine Serum Production
Defenders of the practice point out that FBS is a byproduct, not the reason cows are slaughtered. The pregnant cows were already destined for meat processing, and collecting serum from fetuses that would otherwise be discarded makes use of what would be waste. Critics counter that the scale of the industry, with millions of fetuses processed annually, means that even a byproduct deserves scrutiny if there is a chance it causes suffering. Some animal welfare organizations have pushed for stricter regulations on how quickly blood must be drawn after the mother’s death, and whether the fetus should be confirmed dead before cardiac puncture begins.
FBS collection can only be performed in government-approved facilities, which provides some regulatory oversight.1PubMed Central. Review of the Current Research on Fetal Bovine Serum and the Development of Cultured Meat But enforcement varies by country, and the global nature of the FBS supply chain means serum sourced from regions with less oversight may not meet the same standards.
Why Supply Is Unpredictable and Prices Swing Wildly
FBS prices have historically been volatile, and the root cause is structural: supply is inelastic. Unlike most biological products, you cannot simply scale up production when demand rises. The number of fetuses available depends on how many pregnant cows happen to be culled in a given year, which in turn depends on cattle market economics that have nothing to do with the laboratory supply industry. When cattle prices are high, ranchers hold onto their animals longer and send fewer to slaughter, which means fewer pregnant cows and fewer fetuses.5PubMed Central. Production, pricing, and incentives in the fetal bovine serum market
This disconnect creates a peculiar market dynamic. A researcher who needs FBS for a multi-year project might find prices doubling or tripling from one purchase to the next, with no warning and no alternative supplier who can offer better pricing. Institutions sometimes stockpile large lots when prices dip, creating hoarding behavior that further distorts the market. The result is that FBS represents one of the single largest costs in many cell culture operations, even though the serum itself is technically a slaughterhouse byproduct.6PubMed. Study on the feasibility of using livestock blood as a fetal bovine serum substitute for cultured meat
Batch-to-Batch Variability
Even within the same supplier, no two lots of FBS are identical. The serum’s composition depends on the gestational age of the fetus, the breed of the cow, her diet, geographic origin, and even the season. This variability has long been a headache for researchers doing experiments that demand reproducibility. A cell line that grows beautifully in one lot of FBS may behave differently in the next lot from the same vendor.
Laboratories often deal with this by testing multiple lots before committing to a purchase, selecting the one that performs best for their specific application, and then buying enough of that lot to last through an entire study. This lot-reservation system works but adds cost and logistical complexity. It also means that published experiments using FBS are difficult to replicate exactly, because the precise composition of the serum used is unknown and unreproducible. The addition of animal-derived products introduces batch and lot variations that are a recognized source of experimental variability and represent a major cost in cell culture.7PubMed. Optimization of chemically defined cell culture media–replacing fetal bovine serum in mammalian in vitro methods
Alternatives Gaining Ground
The ethical concerns, supply volatility, and reproducibility problems have all pushed researchers to look for substitutes. The most developed alternative for human cell culture is human platelet lysate, or hPL. Platelet lysate is made from expired or surplus human blood-bank platelets, which are broken open to release the growth factors inside. Multiple systematic reviews have found that hPL performs at least as well as FBS for growing human mesenchymal stem cells, supporting their adhesion, survival, and proliferation.8PubMed Central. Human platelet lysate to substitute fetal bovine serum in hMSC expansion for translational applications: a systematic review The appeal is obvious: if you are growing human cells for eventual clinical use in patients, using a human-derived supplement instead of a bovine one eliminates the risk of transferring animal pathogens and avoids potential immune reactions.
Platelet lysate has been validated across several cell types, including adipose-derived stem cells, and has established itself as a suitable FBS replacement for human cell propagation across applications in cell therapy and tissue engineering.9PubMed. Human platelet lysate: Replacing fetal bovine serum as a gold standard for human cell propagation?10PubMed Central. Human Platelet Lysate as a Functional Substitute for Fetal Bovine Serum in the Culture of Human Adipose Derived Stromal/Stem Cells However, platelet lysate shares one problem with FBS: batch-to-batch variability, since each production run depends on the pooled platelets from different donors. Standardization of hPL manufacturing remains a work in progress.
Chemically Defined and Serum-Free Media
The more radical alternative is to skip biological supplements entirely and use chemically defined media, formulations where every ingredient is a known molecule at a known concentration. These media can be engineered for specific cell types and offer perfect reproducibility between batches, which is a massive advantage for both research and manufacturing. Several commercially available serum-free and xeno-free (containing no animal-derived components) formulations now exist and have been shown to support multiple cell lineages.11PubMed Central. Chemically defined serum-free and xeno-free media for multiple cell lineages
The catch is that developing a serum-free medium for a particular cell type requires extensive optimization. FBS works as a kind of universal buffer: it contains such a complex cocktail of molecules that most cell types find what they need in it. A chemically defined medium has to identify and supply each of those factors individually, and the recipe that works for one cell type may fail completely for another. This customization burden is the main reason FBS has not yet been displaced across the board.
The Cultivated Meat Pressure Point
Nowhere is the push to replace FBS more urgent than in the cultivated meat industry. Growing animal muscle tissue in bioreactors for food requires enormous quantities of growth media, and FBS has traditionally been the go-to supplement. But using fetal calf blood to make a product marketed as cruelty-free is an obvious contradiction. Beyond the ethical optics, the sheer volume of FBS needed to scale cultivated meat to commercial levels would vastly exceed available supply, and the cost would make the final product unaffordable.6PubMed. Study on the feasibility of using livestock blood as a fetal bovine serum substitute for cultured meat
This is why serum-free media development is treated as a make-or-break challenge for the industry. Replacing FBS in cultivated meat requires food-grade media that can supply nutrients, maintain the right ionic environment, deliver precise growth signals, and protect cells from physical stress in large bioreactors.12PubMed. Serum-free media for cultivated meat: from cellular mechanisms to cost-effective bioprocess design Several startups and academic groups have made progress, and most companies in the space now claim to have moved to serum-free formulations for at least part of their production process. Whether those formulations can maintain performance at true industrial scale remains an open question.
What Many People Get Wrong About FBS
A common misconception is that cows are slaughtered specifically to harvest FBS. In reality, the pregnant cows are culled from herds for reasons unrelated to serum production: they may be aging out of a dairy operation, struggling with fertility, or no longer economically productive. The fetus is discovered after the fact. FBS collection does not drive slaughter decisions; it rides on top of them.
Another misunderstanding involves the word “serum” itself. People sometimes assume FBS is whole blood, or that it contains red blood cells. Serum is specifically the liquid fraction left over after blood has clotted and the cellular components have been removed. It contains no cells, no hemoglobin, and no clotting factors. This is precisely why it is useful: it provides dissolved growth factors and nutrients without introducing the cellular complexity of whole blood into a culture system.
A third point of confusion is the idea that FBS is easy to replace. While alternatives exist and are improving rapidly, the reality is that FBS remains deeply embedded in protocols across thousands of laboratories worldwide. Many cell lines have been optimized over decades to grow in FBS-supplemented media, and switching to a serum-free formulation often requires revalidating entire experimental workflows. The transition is happening, but it is measured in years, not months.